Evaluation of the effectiveness of the use of collagen cones in the post-extraction socket preservation in patients on temporary antithrombotic therapyстатья
Статья опубликована в журнале из списка RSCI Web of Science
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из перечня ВАК
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 15 мая 2024 г.
Аннотация:When taking antiplatelet agents and anticoagulants, a change in the hemostatic properties of blood leads to a decrease in its viscosity and the adhesion strength of platelets, which is reflected in the slowing down of the formation of a blood clot and the likelihood of its detachment. The aim of this study was to study the effectiveness of the use of collagen cones for the socket preservation in patients temporarily receiving antithrombotic therapy. Materials and methods. The pilot study, conducted from December 2020 to May 2021, included 27 patients. The main group consisted of 17 patients in need of surgical debridement of the oral cavity, aged 30 to 45 years, without a somatically burdened history, who underwent SARS CoV-2. The comparison group consisted of 10 people within the same age, but did not receive any medications on a regular basis. Collagen cones Alvokon were used to preserve alveolar sockets. To assess osteogenesis, all patients underwent X-ray examinations of the area of interest immediately after removal and after 1 month. Results. In patients of both groups, the density of the bone pattern in the area of interest increased, which indicates normal osteogenesis. However, in the patients of the main group, the bone density in the areas of interest comparable to the segments of the patients in the comparison group was slightly lower. Discussion. The results of the pilot study show the effectiveness of collagen cones not only as an osteoplastic material, but also as an excellent local hemostatic. Conclusion. Collagen cones are recommended for use in patients receiving antithrombotic therapy with selective inhibitors of coagulation factors Xa, in order to prevent the development of early and late local bleeding during surgical debridement of the oral cavity.